Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

4basebio Plc (4BB) Share Price

Price 790.00p on 17-10-2025 at 18:35:06
Change 30.00p 3.95%
Buy 800.00p
Sell 720.00p
Last Trade: Buy 33.00 at 790.00p
Day's Volume: 56
Last Close: 790.00p
Open: 760.00p
ISIN: GB00BMCLYF79
Day's Range 790.00p - 790.00p
52wk Range: 715.00p - 1,380.00p
Market Capitalisation: £122.33m
VWAP: 764.93643p
Shares in Issue: 15.48m

4basebio Plc (4BB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 33 790.00p Suspected BUY Trade
16:35:27 - 17-Oct-25
Buy* 1 762.44p Ordinary
11:24:03 - 17-Oct-25
Buy* 1 800.00p SI Trade
10:23:00 - 17-Oct-25
Sell* 21 724.00p Ordinary
08:30:19 - 17-Oct-25
Sell* 10 724.00p Ordinary
14:04:10 - 16-Oct-25
Buy* 1 762.44p Ordinary
13:45:07 - 15-Oct-25
Sell* 415 724.00p Ordinary
15:52:05 - 14-Oct-25
Sell* 65 750.00p Ordinary
12:00:00 - 14-Oct-25
Sell* 665 750.00p Ordinary
14:45:16 - 13-Oct-25
Sell* 2 724.00p Ordinary
11:27:45 - 13-Oct-25
See more 4basebio Plc trades

4basebio Plc (4BB) Share Price History

Time period:
to
Date Open High Low Close Volume
17th Oct 2025 (Fri) 760.00 790.00 790.00 790.00 56
16th Oct 2025 (Thu) 760.00 760.00 760.00 760.00 10
15th Oct 2025 (Wed) 760.00 760.00 760.00 760.00 1
14th Oct 2025 (Tue) 760.00 760.00 755.00 760.00 480
13th Oct 2025 (Mon) 760.00 720.00 720.00 760.00 699
10th Oct 2025 (Fri) 775.00 775.00 760.00 760.00 625
9th Oct 2025 (Thu) 775.00 775.00 775.00 775.00 38
8th Oct 2025 (Wed) 775.00 795.00 775.00 775.00 131
7th Oct 2025 (Tue) 775.00 775.00 775.00 775.00 9
6th Oct 2025 (Mon) 775.00 775.00 775.00 775.00 252
3rd Oct 2025 (Fri) 775.00 750.00 750.00 775.00 653
2nd Oct 2025 (Thu) 775.00 775.00 775.00 775.00 55
1st Oct 2025 (Wed) 775.00 775.00 775.00 775.00 2,110
30th Sep 2025 (Tue) 730.00 795.00 795.00 795.00 2,445
29th Sep 2025 (Mon) 725.00 790.00 725.00 730.00 2,016
26th Sep 2025 (Fri) 725.00 725.00 725.00 725.00 17
25th Sep 2025 (Thu) 725.00 725.00 725.00 725.00 266
24th Sep 2025 (Wed) 725.00 725.00 725.00 725.00 533
23rd Sep 2025 (Tue) 720.00 725.00 720.00 725.00 877
22nd Sep 2025 (Mon) 822.50 822.50 715.00 720.00 7,766
19th Sep 2025 (Fri) 832.50 832.50 822.50 822.50 1,089
See more 4basebio Plc price history

4basebio Plc (4BB) Regulatory News

Date Source Headline
10th Oct 2025 11:30 am PRN Result of Extraordinary General Meeting
30th Sep 2025 4:20 pm PRN Director Dealing
29th Sep 2025 7:00 am PRN Half-year Report
22nd Jul 2025 7:00 am PRN Employee Long Term Incentive Plan and Issue of Equity
8th Jul 2025 10:30 am PRN Director Appointment, Board Change
3rd Jul 2025 7:00 am PRN Holding(s) in Company
3rd Jul 2025 7:00 am PRN Holding(s) in Company
2nd Jul 2025 7:00 am PRN Holding(s) in Company
2nd Jul 2025 7:00 am PRN Holding(s) in Company
27th Jun 2025 6:05 pm PRN Result of AGM
See more 4basebio Plc regulatory news

4basebio Plc (4BB) Share News

EARNINGS: Next 15 profit falls; 4basebio and Mollyroe losses widen

1st Oct 2025 12:57

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

20th Jun 2025 12:02

Read More

4basebio expects to sustain DNA sales growth momentum in 2025

27th May 2025 11:57

(Alliance News) - 4basebio on Tuesday reported a wider pretax loss in 2024, despite higher revenue, and said it is optimistic about the year to come. Read More

IN BRIEF: 4basebio hits "critical milestone" as it secures GMP licence

2nd Apr 2025 09:51

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Secures good manufacturing practice, or GMP, certification for its UK DNA manufacturing facility from the UK Medicines & Healthcare Products Regulatory Agency. This authorises it to manufacture and supply investigational medicinal product drug substance and critical starting biological medicinal materials used in advanced therapy medicinal products from its Cambridge facility, says the firm. Adds that the certification strengthens its position in the advanced therapeutics field and progresses it towards commercialisation and patient care for a range of advanced therapies. Chief Executive Heikki Lanckriet says: "Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company." Read More

IN BRIEF: 4basebio names Gabe Longoria as new chief commercial officer

8th Jan 2025 11:47

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Names Gabe Longoria as the new chief commercial officer. Longoria was previously CCO at Astrea Bioseparations Ltd. The appointment follows a GBP40 million investment into 4basebio by Elevate Medical Technologies and M&G Investment Management Ltd, which completed in November. This is a "key milestone" for the company. Read More

See more 4basebio Plc news
FTSE 100 Latest
Value9,354.57
Change-81.52

Login to your account

Forgot Password?

Not Registered